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The market authorization procedure for medicinal products for human use is relying on
their demonstrated efﬁcacy, safety, and pharmaceutical quality. This applies to all med-
icinal products whether of chemical or biological origin. Since October 2009, the ﬁrst
advanced therapy medicinal product (ATMP) has been authorized through the centralized
procedure. ATMPs are gene therapy medicinal products, somatic cell therapy medicinal
products or tissue-engineered products. An appropriate ATMP – Regulation is dealing with
ATMP requirements.Two exemptions are foreseen to the ATMP Regulation: (a) Products,
which were legally on the Community market when the Regulation became applicable,
should comply to the Regulation by December 30, 2012. (b)The hospital exemption rule for
non-routine products for an individual patient. In this work we explored whether the actual
application of the Regulation on ATMPs is in line with the aim of the Regulation in terms of
guaranteeing the highest level of health protection for patients. Based on the analysis of
the relative efﬁcacy of the only EC authorized ATMP and its exempted alternatives, there
is evidence against this Regulation 1394/2007 assumption.
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INTRODUCTION
The market authorization (MA) procedure for medicinal prod-
ucts for human use is relying on their demonstrated efﬁcacy,
safety, and pharmaceutical quality (The European Parliament
and the Council of the European Union, 2001). This applies to
all medicinal products whether of chemical (e.g., blood pres-
sure lowering diuretic) or biological (e.g., anti-inﬂammatory
monoclonal antibody) origin. Modern biotechnology medici-
nal products obtain market approval through the centralized
procedure as detailed in the EC Regulation 726/2004 (The
European Parliament and the Council of the European Union,
2004).
Since 2008, a “lex specialis” – Regulation (EC) No 1394/2007
(The European Parliament and the Council of the European
Union, 2007) – applies to advanced therapy medicinal prod-
ucts (ATMPs); these ATMPs are pharmaceuticals with high com-
plexity (The Committee for Advanced Therapies (CAT) and the
CAT Scientiﬁc Secretariat, 2010) linked to their development,
manufacturing, or administration process.
The Regulation highlights the following:
• It provides an explicit ATMP deﬁnition: ATMPs are gene
therapy, somatic cell therapy, or tissue-engineered medicinal
products.
• An ATMP must comply with the existing MA requirements
(quality,safety,andefﬁcacy)andthepost-marketingpharmaco-
vigilancerules.ForMA,thecentralizedprocedureismandatory:
it aims to pool Community expertise and ensure a high level of
scientiﬁc evaluation and facilitate access to market.
• Because of the complexity of ATMPs, a new Committee for
Advanced Therapies (CAT) has been installed. The CAT’s main
responsibilities are:
• The mandatory evaluation of MA applications by provid-
ing opinions to the Committee for Medicinal Products for
Human Use (CHMP); the CHMP may adopt or refuse the
CAT opinion.
• The optional scientiﬁc certiﬁcation (art. 18) of quality
and non-clinical data of a proposed ATMP-compound in
development.
• The optional scientiﬁc recommendation on ATMP-
classiﬁcation (art. 17), prior to their clinical development.
The CAT (The Committee forAdvanced Therapies (CAT) and the
CAT Scientiﬁc Secretariat, 2010) is a multidisciplinary scientiﬁc
expert committee: it also focuses on the scientiﬁc developments
in the ﬁeld. There is no doubt about the huge scientiﬁc, regula-
tory, and ethical challenges triggered by these complex products
and a speciﬁc expert committee for ATMPs is necessary to deal
withthesechallenges(similartothecreationof theCommitteeon
Orphan Medicinal Products for drugs used in rare diseases) and
beneﬁcial to all relevant public and private stakeholders.
• The Tissues and Cells Directive (2004/23/EC) applies to dona-
tion, procurement and testing of human tissues and cells.
• TheRegulationdeﬁnesthepre-andpost-authorizationrequire-
ments:GMPandGCPstandards,productfollow-uponefﬁcacy
and safety, risk management plan, and traceability.
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• The Regulation also provides incentives for applicants by offer-
ing scientiﬁc advice at various development steps at sub-
stantially reduced fees, mainly to small- and medium-sized
enterprises and hospitals.
The aim of this ATMP – Regulation is to offer a consolidated
regulatory framework for these innovative medicines and it was
designed (European Medicines Agency,2011a)t o
“...ensure the free movement of these medicines within the
European Union (EU), to facilitate their access to the EU
market, and to foster the competitiveness of European phar-
maceutical companies in the ﬁeld, while guaranteeing the
highest level of health protection for patients.”
Two exemptions are foreseen to the ATMP Regulation:
1. Products, which were legally on the Community market on
December 30, 2008 (when the Regulation became applicable),
should be compliant to the Regulation requirements no later
than December 30, 2012. These products will be withdrawn
from the market afterward if no centralized MA application
has been submitted and granted.
2. Exemptions to the Regulation are also deﬁned under the
hospital exemption rule:
“Advanced therapy medicinal products which are prepared
on a non-routine basis according to speciﬁc quality stan-
dards, and used within the same Member State in a hospital
under the exclusive professional responsibility of a medical
practitioner, in order to comply with an individual medical
prescription for a custom-made product for an individual
patient,shouldbeexcludedfromthescopeof thisRegulation
whilst at the same time ensuring that relevant Community
rules related to quality and safety are not undermined.”
Theﬁrstexemptionrelatestoatransitionperiodallowingexist-
ing products to evolve toward ATMP-compliance. The hospital
exemption allows hospitals and medical practitioners to pro-
vide ATMP-classiﬁed products to patients, e.g., in case of high
unmet medical need because there is no authorized ATMP alter-
native available. Concrete examples are tumor vaccines, made
by hospitals for treating cancer patients having no treatment
alternatives.
The hospital exemption is limited to non-routine products,
custom-made for individual patients. There is discussion on the
correct interpretation of these words: for instance,are autologous
products de facto not for individual patients?
Anyway, as a consequence,ATMPs with different development
tracks and quality control procedures may co-exist on the Com-
munitymarketsatisfyingdifferentstandardsonefﬁcacy,safetyand
quality;for hospital exemptions the Regulation requires traceabil-
ity, quality, and pharmaco-vigilance standards to be “equivalent”
to standards for centrally authorized products. Manufacture of
ATMPs under hospital exemption has to be authorized by the
appropriatememberstatetoensureappropriatequality.Thereare
no efﬁcacy criteria mentioned.
Even if there are good reasons explaining why these exemp-
tions are needed (e.g., the realism of a transition period, the
ethical need to deal with unmet medical need) the Regulation
allows exemptions on the market without concrete requirement
on demonstrated quality, efﬁcacy, and safety.
OBJECTIVES
InthisworkweexploredwhethertheactualapplicationoftheReg-
ulationonATMPsisinlinewiththeaimoftheRegulationinterms
of guaranteeing the highest level of health protection for patients
by focusing on ATMPs and their exemptions. Health protection
is understood as ensuring efﬁcacy, safety, and pharmaceutical
quality.
Theaimisexploratoryonly:itintendstoenhancethediscussion
on the effectiveness of the Regulation, based on early experience.
This work does not pretend to provide judicious and deﬁnite
answers to the complex economic and ethical issues relating to
regulatory exemptions.
METHODS
We searched the available evidence for ATMP products being
centrally authorized (EC authorized) and for their available alter-
natives (non-EC authorized,exemptions).We started by checking
the EMA-website (European Medicines Agency, 2012) for autho-
rized ATMPs till December 2011. We then searched the medical
literature published on “EC authorized” and on “non-EC autho-
rized”ATMPs. Due to the exploratory purpose, we did not make
an exhaustive systematic literature search as would be required
for a formal health technology assessment: our interest was not to
focusontheperformanceofasingleproductbuttoexplorewhether
clinically relevant differences might exist between products,which if
it was the case would be considered as a threat to the aim of the
Regulation of guaranteeing the highest level of health protection for
patients.
Many competing interventions have not been compared
directly: because the literature search ended with only one ATMP
beingavailableasECauthorizedproductandwedidnotﬁndtrials
withhead-to-headcomparisons(seeResults)between“ECautho-
rized” and “non-EC authorized” ATMPs, we performed adjusted
indirect treatment comparisons (ITCs). The on line application
provided by the Canadian Agency for Drugs and Technologies in
Health(CADTH;CanadianAgencyforDrugsandTechnologiesin
Health,2011)wasused;thispublicavailableAgency’sapplicationis
basedonappropriatemethodologyforadjustedcomparisons,with
an explicit user guide offering step by step assistance in the analy-
sis. The ITC application can cope with simple and more complex
(multiple comparisons) settings; in this work we simply analyzed
the EC authorized ATMP with each of the non-EC authorized
ATMPs based on a common comparator.
The main ITC assumption of independence among trials was
achieved by excluding published study results if they originated
from the same study populations.
Theevidencefoundintheliteratureuseddifferentclinicalend-
pointspertrial.Onlystandardizedtreatmenteffectscouldthenbe
used for ITC, losing the clinical relevance of the individual end-
points:tocopeforthisloss,weconsideredthestrengthof theeffect
ascategorizedbyCohen(ValentineandCooper,2003)t oappr o xi-
matetheclinicalrelevanceoftheresults.ThestrengthoftheCohen
effectsizeisgenerallyclassiﬁedasfollows:smalleffectif difference
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≥0.2, medium effect if difference ≥0.5, and large effect if differ-
ence ≥0.8. We assumed that “large effects” would be considered
clinically relevant effects.
No adjustment was done for multiple testing: the signiﬁcance
level was set at 0.05.
RESULTS
Despite the Regulation being implemented by the end of 2008,
only six applications have been submitted for MA of four ATMPs
(European Medicines Agency,2012):
• In June 2009 a positive opinion for MA was adopted for
ChondroCelect, which is an autologous product containing
chondrocytes for treatment of deep cartilage injuries of the
knee.
• In July 2009, the product Contusugene Ladenovec was with-
drawnbytheapplicant:theproductwasintendedfortreatment
of squamous cell carcinoma of head and neck.
• In December 2009, the CAT adopted a negative opinion on the
MA application of Cerepro, a gene therapy product intended
for treatment of cerebral cancer (high grade glioma); the
manufacturer withdrew its application in March 2010.
• A negative CAT opinion was adopted for the MA application
of Glybera in June 2011; Glybera is a gene therapy product
intended for use in severe lipid metabolic disease. On re-
examination of Glybera in October 2011, the CAT adopted a
positive opinion but this was not endorsed by the CHMP.
Market authorization was granted by the Commission in October
2009 for ChondroCelect (TiGenix company; European Medicines
Agency, 2011b), indicated for the repair of knee cartilage defects.
Osteoarthritis (OA) is a public health concern (Clouet et al.,
2009): during OA degenerative processes, major modiﬁcations of
articular cartilage are observed at the tissue, cellular, and mol-
ecular levels. Articular cartilage, if damaged, hardly heals, and
traumatic loss of cartilaginous tissue therefore may lead to the
subsequent development of OA-lesions (e.g. of knee,hip...). The
therapeutic options combine pharmacological treatments and tis-
sue engineering toward regenerative medicine to induce cartilage
repair.
ChondroCelect is still the only EC authorized ATMP: non-EC
authorized chondrocytes for knee cartilage repair also exist. All
chondrocyteproductsareimplantedinthepatientkneebyasurgi-
caltechniquecalledautologouschondrocytesimplantation(ACI).
In this work we will further identify these products as either CCI
(for EC authorized chondrocytes, ATMP) and ACI (for non-EC
authorized chondrocytes).
A simpliﬁed search in PubMed (August 18, 2011) was per-
formed using the key words “autologous chondrocyte,” limiting
the search to controlled trials on human beings and further
limited to papers published in English between 2008 (imple-
mentation year of the Regulation on ATMPs) and mid august
2011. The PubMed literature search resulted in 50 references (see
Appendix).
Because the control group in the clinical development (Euro-
peanMedicinesAgency,2011c)programofCCIwasmicrofracture
(a surgical micro-bleeding technique releasing stem cells), only
ACI-studies including microfracture (MF) as control group could
be selected for making ITC between the clinical outcome of CCI
and ACI.
Across the studies a variety of clinical end-points was used
with only some being considered as validated end-points for clin-
ical research by EMA (The Committee for Advanced Therapies,
2010).
From the 50 references, only four papers on three stud-
ies included clinical results from ACI and MF: 45 papers were
excluded because the study included only observational non-
controlled data, because the study related to subgroups from
the three main studies, because lack of (knee) clinical outcome
results or because another comparator than MF was used. There
was one systematic review (Harris et al., 2010) which included
the results of the three identiﬁed primary studies. Moreover, the
review authors took care of standardizing the clinical outcome
results of the included trials which is particularly relevant because
the variety of clinical and structural end-points (The Commit-
tee for Advanced Therapies, 2010) used in the included stud-
ies would otherwise be a hurdle to any meaningful quantitative
analysis.
For making ITCs between CCI and each of the various ACI-
products, the standardized results of the systematic review were
subsequently used.
The review authors included seven trial reports on >900
patientsinwhichCCIandACI-productswerecomparedtoMF.In
our opinion,for two trials,the results of the same patient popula-
tionwerepresentedattwodifferentlengthsof follow-up:toobtain
independent trial data, only one manuscript (the most recent
one) per patient population was kept, resulting in ﬁve datasets
for further comparison.
Indirect treatment comparisons can only be valuable if the
compared patient populations across trials are similar (Jansen
et al., 2011) with respect to modiﬁers of the relative treat-
ment effect (e.g., important prognostic factors): because MF
is the common comparator the appropriateness of the trial
patient population with respect to the lesion size needs to be
addressed. One study (reference Basad et al., 2010 in the review)
was excluded because it enrolled patients with cartilage lesions
larger than 4cm2, which are commonly accepted to be unsuit-
able for MF treatment (The Committee for Advanced Therapies,
2010).
Accordingly,the standardized results from four products (CCI,
ACI 1–3) were compared.
The standardized direct mean treatment differences and the
95% CI of the mean differences between the various chondrocyte
products and MF are as follows (extracted from p. 2226 of Harris
et al.,2010).
Product (reference as
mentioned in the
systematic review)
Standardized mean
treatment difference
with MF
95% Conﬁdence
interval
CCI (Saris et al., 2009) 1.52 (1.03; 2.01)
A C I1( Kon et al., 2009) 0.76 (0.31; 1.21)
A C I2( Basad et al., 2004) 0.92 (−0.06; 1.82)
A C I3( Knutsen et al., 2007) −0.40 (−0.79; 0.01)
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Two of the four chondrocyte products could demonstrate sig-
niﬁcant clinical beneﬁt as compared to MF (CCI, ACI1): the
standardized mean treatment difference could be classiﬁed as
“large effect.” The lower limit of the conﬁdence interval of the
CCI standardized clinical effect still exceeded the “large effect”
threshold; both ACI2 and ACI3 products had a non-signiﬁcant
meandifferencewithMFbuttheirconﬁdenceintervalsstillinclude
“large effect”sizes.
Based on the individual study results versus MF, the ITC
between the chondrocyte products could be computed and are
summarized as follows (see statistical output from CADHT-tool
in Appendix).
Treatment effect Estimate of mean Δ 95% LCL 95% UCL
CCI–ACI 1 0.76 0.095 1.425
CCI–ACI 2 0.60 −0.460 1.660
CCI–ACI 3 1.92 1.287 2.553
ACI 1–ACI 2 −0.16 −1.202 0.882
ACI 1–ACI 3 1.16 0.558 1.762
ACI 2–ACI 3 1.32 0.298 2.342
The bold signiﬁcance relates to any statistically signiﬁcant effect being 0.8 or
higher, as this is the threshold of large treatment effects (Cohen effect size).
From the six possible ITCs four ITCs yield signiﬁcant differ-
ences: CCI is signiﬁcantly superior to ACI1; CCI,ACI1, and ACI2
are signiﬁcantly superior toACI3.All signiﬁcant mean differences
can be classiﬁed as“large”treatment effects.
DISCUSSION
Advanced therapy medicinal products are human cells and tis-
sues or products with a genetic mode of action; they gener-
ate huge expectations but are also associated to new signiﬁcant
threats [The Committee for Advanced Therapies (CAT) and the
CAT Scientiﬁc Secretariat, 2010] including tumorigenicity, cell
(de)differentiation,andpatientintegration.TheATMPRegulation
1394/2007aimstofacilitatethepatientaccesstotheseproductsand
tofosterthecompetitivenessof Europeanpharmaceuticalcompa-
nies in the ﬁeld, while guaranteeing the highest level of health
protection for patients.
The ATMP-portfolio for which the CAT has been involved in
certiﬁcation, classiﬁcation, and MA is available via the monthly
CAT-reports (European Medicines Agency,2012):
• By the end of 2011 only one certiﬁcation procedure for quality
and non-clinical data has been requested (2009) and adopted
(2010).
• Fifty-three requests for ATMP-classiﬁcation have been submit-
ted of which 51 reached the recommendation stage:46 (90.2%)
have been classiﬁed ATMP.
• Six applications for MA of four products have been evaluated
leading to one authorized ATMP.
The certiﬁcation procedure intends to create incentives for SMEs
to develop ATMPs; the only certiﬁcation procedure ﬁnished by
now clearly threatens this objective. Fortunately, the number of
submitted ATMP-classiﬁcation requests is sufﬁciently large to
identify the actual main areas for ATMP-development in Europe.
Among the 46 ATMP-classiﬁed products (available from web-
site):
• Seventeen (37.0%) are somatic cell therapy products.
• Seventeen (37.0%) are tissue-engineered products.
• Eleven (23.9%) are genetic therapy products.
• One (2.1%) is classiﬁed asATMP without further speciﬁcation.
The split per therapeutic area is as follows:
Disease:
ATMP
Cancer Cardio-
vascular
Inﬂammatory
and auto-
immune
Skin Other
Somatic cell
therapy
814 1 3
Tissue
engineered
15 4 7
Gene therapy 3 1 7
Total (%) 12 (26.7) 6 (13.3) 5 (11.1) 5 (11.1) 17 (37 .8)
The oncology area captures 12 ATMPs mainly classiﬁed as
somatic cell (8) therapy. Cell compounds for treatment of debil-
itating inﬂammatory (e.g., multiple sclerosis) or auto-immune
diseases (e.g.,pancreatitis) and tissue-engineered products for use
in severe cardiovascular disease (e.g., myocardial infarction) or
skin disease (mainly treatment of burn wounds) are in devel-
opment; applications are studied in metabolic disease, ophthal-
mology, bone, and cartilage disease, but also in muscular, and
neurological disease (e.g., Parkinson disease).
Clearly,these are therapeutic areas with a huge disease burden,
linked to a high unmet medical need in which ATMPs may be of
value by their unique mode of action, aiming at regenerating cell
functionality,and tissue integrity.
After 4years the net outcome of the ATMP Regulation
1394/2007 is still limited as only one ATMP has been autho-
rized and only one request for certiﬁcation has been ﬁnalized,
despite the fact that already 46 compounds have been classiﬁed
as ATMP. In the US, the Center for Biologics Evaluation and
Research (CBER; Food and Drug Administration, 2012a) within
FDA regulates biological products for human use, both investiga-
tional and licensed. CBER regulates biological products including
genetherapy,humantissue,andcellsunderapplicablefederallaws,
includingthePublicHealthServiceActandtheFederalFood,Drug
and Cosmetic Act. By now, no gene therapy has been authorized
to market but various human tissue (Food and Drug Adminis-
tration, 2012b) and cell products are authorized including the
autologouscellularimmunotherapyproductProvenge(Dendreon
company)fortreatmentof prostatecancerandtheculturedchon-
drocytes product Carticel (Genzyme company). There is no “lex
specialis.”
Exemptions,speciﬁctotheEuropeanRegulationincludeatem-
porary exemption (till end of 2012) for products existing prior
to the implementation of the Regulation and a permanent hos-
pital exemption for non-routinely made products for individual
patients.Inthisworkweaimedtoverifywhetherdifferentdevelop-
ment tracks for these complex medicinal products are not putting
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the patient health protection (deﬁned as ensuring efﬁcacy, safety,
and pharmaceutical quality) at risk.
The only ATMP authorized in the Community market is a
medicinal product containing chondrocytes for knee cartilage
regeneration.
Based on the literature search on the “EC authorized” and
“non-EC authorized” chondrocyte products, ITC could be made
between four different products. Our results indicate statisti-
cally signiﬁcant and clinically relevant differences in efﬁcacy exist
between these four cell products.
The Regulation 1394 is based on the assumption that “EC
authorized” and exempted ATMPs provide similar health patient
beneﬁt. But based on our indirect results, the probability of a
healthy patient outcome is strongly dependent on the product
administered;thisputstheexemptionruleoftheRegulationunder
pressure.
From a pharmacological point of view, similar (the highest)
healthpatientbeneﬁtamongexemptedandnon-exemptedATMPs
is assuming there would be a class effect (acknowledging this may
beadifﬁcultconceptforautologousproducts).Butevenforaclass
of conventionalmedicinalproductslikeACE-inhibitors,quantita-
tivedifferencesalteringthetherapeuticbeneﬁtsforspeciﬁcpatient
populations may exist as shown by Furberg (2000); the author’s
conclusionwasthatuntesteddrugsof aclassshouldbeconsidered
unprovendrugs.Ifthisisthecaseforconventionalmedicinalprod-
ucts, how conﬁdent can we then be in assuming that the highest
health beneﬁt will be ensured between more complex medicinal
products?
Finally, more speciﬁcally in the orthopedic surgery ﬁeld, the
review byVavkenandSamartzis(2010)didmention:“...AlsoACI
canhardlybeseenasone,standardizedtreatment,duetotechnical
differences, and inter-patient variation in cell quality.”
Based on the above, in the therapeutic area of orthopedic
surgery, there is evidence to say clinically relevant differences
in health outcome exist between the authorized ATMP and the
exemption products.
This study has many limitations. Only one medicinal product
couldbeinvestigateddespitetheRegulationbeingapplicablefrom
the end of 2008.
The evidence on different health outcome beneﬁts between the
ATMPanditsexemptionproductsisbasedonITCfromonerecent
systematic review in the orthopedic surgery ﬁeld. There is a lack
of controlled trials with acceptable quality in this area (Hanzlik
et al., 2009): in a review of all articles published in The Journal of
BoneandJointSurgeryintheyears1975,1985,1995,and2005the
percentageof Level-Istudiesincreasedfrom4%in1975to21%in
2005. Despite this positive trend for increasing the percentage of
high level evidence trials there is still substantial opportunity for
improvement.
The individual clinical trial end-points were transformed into
one standardized outcome affecting the interpretation of clinical
relevance: to deal with this,we used the common cut-off for large
treatment effects to identify clinical relevant effects.
We analyzed efﬁcacy and did not focus on other elements of
patient health beneﬁt like safety or pharmaceutical quality. Inves-
tigating differences in safety issues might be very hard because
of the small number of patients enrolled in the considered stud-
ies (maximum of 118 patients randomized): the estimate of the
incidence of adverse events for any compound will lack precision.
Differences in pharmaceutical quality could not be investigated
because of lack of public available documentation. It is a clear
advantage of EC centrally authorized medicinal products that
important regulatory documentation is easily available: the sum-
mary of product characteristics (SPC) and the European public
assessment report (EPAR) provide relevant insights to patient and
health care worker on efﬁcacy, safety, and pharmaceutical qual-
ity of the medicinal product. The extent of documentation on
non-EC authorized products is differing between member states,
delivering companies or hospitals, and may be hard to obtain for
any external party.
We did not analyze how exemptions to ATMPs may affect
the internal market functioning because of the limited experi-
ence with only one ATMP available. Obviously differences in
development track will yield differences in the necessary R&D
resources, which may result in substantial product price differ-
ences: this is a hurdle for the applicant submitting a centrally
authorized ATMP when lower priced exempted alternatives are
on the market. In many member states a price premium can only
be granted if added therapeutic value compared to the alternative
has been demonstrated. But this direct comparison will proba-
bly lack, as it is the case for the 1st ATMP containing cultured
chondrocytes:thedesignsectionoftheCAT-ReﬂectionPaper(The
CommitteeforAdvancedTherapies,2010)inthisﬁeldclearlyspec-
iﬁes “licensed products” as valid comparators that can be used in
controlled trials. It further states “...However, the use of a non-
authorized medicinal product is problematic as it has not been
validated for clinical use and the quality of the product has not
been assessed.”
Valid approaches to adjusted ITC will be necessary but the
acceptability of indirect evidence may be different between
competent authorities increasing the 4th hurdle for ATMPs.
As the European Pharmaceutical Forum and the European
Transparency Directive (The Council of the European Communi-
ties, 1989; European Commission, 2012) explicitly ask competent
authorities on pricing and reimbursement to take decisions based
on objective and veriﬁable criteria and to be well aligned with the
estimated value of medicines, the question may arise how these
member states will determine the relative value of an ATMP in
comparison to exempted alternatives with assumed but unproven
effect.
In conclusion, based on the analysis of the relative efﬁcacy
of the only EC authorized ATMP and its exempted alterna-
tives, there is evidence against the Regulation 1394/2007 assump-
tion of ensuring the highest level of patient health protection
is maintained among each of these products. The ethical need
for exemption must be balanced with the upcoming evidence
of differences in health outcome between EC authorized and
non-EC authorized ATMP products. The scheduled review by
the Commission by the end of 2012 of the application of the
Regulation should include an assessment of the likelihood of sim-
ilar health outcome among ATMPs with different development
tracks.
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APPENDIX
RESULTS FROM THE ITC PERFORMED WITH THE CADHT-APPLICATION
CCI–ACI1
Estimate, 95% LCL, 95% UCL, Reverse
1.52, 1.03, 2.01, n
0.76, 0.31, 1.21, y
Indirect Estimate: Treatments (1,3)
Effect measure: Mean Difference Estimate: 0.76
95% Conﬁdence interval: 0.095, 1.425
CCI–ACI2
Estimate, 95% LCL, 95% UCL, Reverse
0.92, −0.06, 1.82, y
1.52, 1.03, 2.01, n
Indirect Estimate: Treatments (1,3)
Effect measure: Mean Difference Estimate: 0.6
95% Conﬁdence interval: −0.46, 1.66
CCI–ACI3
Estimate, 95% LCL, 95% UCL, Reverse
1.52, 1.03, 2.01, n
−0.4, −0.79, 0.01, y
Indirect Estimate: Treatments (1,3)
Effect measure: Mean Difference Estimate: 1.92
95% Conﬁdence interval: 1.287, 2.553
ACI1–ACI2
Estimate, 95% LCL, 95% UCL, Reverse
0.92, −0.06, 1.82, y
0.76, 0.31, 1.21, n
Indirect Estimate: Treatments (1,3)
Effect measure: Mean Difference Estimate: −0.16
95% Conﬁdence interval: −1.202, 0.882
ACI1–ACI3
Estimate, 95% LCL, 95% UCL, Reverse
0.76, 0.31, 1.21, n
−0.4, −0.79, 0.01, y
Indirect Estimate: Treatments (1,3)
Effect measure: Mean Difference Estimate: 1.16
95% Conﬁdence interval: 0.558, 1.762
ACI2–ACI3
Estimate, 95% LCL, 95% UCL, Reverse
0.92, −0.06, 1.82, n
−0.4, −0.79, 0.01, y
Indirect Estimate: Treatments (1,3)
Effect measure: Mean Difference Estimate: 1.32
95% Conﬁdence interval: 0.298, 2.342
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